Silexion Therapeutics Announces 1-For-24 Reverse Share Split, Trading On Split-Adjusted Basis To Begin On November 11

Trading on a split-adjusted basis will begin at market open on November 11, 2026.

This adjustment is expected to help Silexion regain compliance with the Nasdaq minimum bid price requirement, enhance its market position, and support its clinical progress with SIL204

Grand Cayman, Cayman Islands, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-24 reverse share split of its ordinary shares. The reverse share split will become effective after market close on November 10, 2026, and the Company’s ordinary shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at market open on November 11, 2026, under the existing ticker symbol "SLXN." The new CUSIP number that has been assigned to the post-reverse split shares (to begin trading on November 11, 2026) is G1281K163.

As a result of the reverse share split, every twenty-four (24) ordinary shares of Silexion issued and outstanding will be automatically combined into one share. The par value of the ordinary shares will be proportionately increased, from $0.135 per share to $3.24 per share, and no fractional shares will be issued. Shareholders that are direct participants in the DTC system and that are entitled to fractional shares will each receive a rounded-up whole share.